Treatment of hypertriglyceridemia: a review of current options
Jazyk angličtina Země Česko Médium print
Typ dokumentu časopisecké články, práce podpořená grantem, přehledy
PubMed
26680666
DOI
10.33549/physiolres.933199
PII: 933199
Knihovny.cz E-zdroje
- MeSH
- chování snižující riziko * MeSH
- hypertriglyceridemie krev terapie MeSH
- hypolipidemika terapeutické užití MeSH
- lidé MeSH
- niacin terapeutické užití MeSH
- omega-3 mastné kyseliny terapeutické užití MeSH
- randomizované kontrolované studie jako téma metody MeSH
- rizikové faktory MeSH
- statiny terapeutické užití MeSH
- triglyceridy krev MeSH
- výsledek terapie MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
- Názvy látek
- hypolipidemika MeSH
- niacin MeSH
- omega-3 mastné kyseliny MeSH
- statiny MeSH
- triglyceridy MeSH
Hypertriglyceridemia is an important marker of increased levels of highly atherogenic remnant-like particles. The importance of lowering plasma levels of triglycerides (TG) has been called into question many times, but currently it is considered an integral part of residual cardiovascular risk reduction strategies. Lifestyle changes (improved diet and increased physical activity) are effective TG lowering measures. Pharmacological treatment usually starts with statins, although associated TG reductions are typically modest. Fibrates are currently the drugs of choice for hyperTG, frequently in combination with statins. Niacin and omega-3 fatty acids improve control of triglyceride levels when the above measures are inadequately effective. Some novel therapies including anti-sense oligonucleotides and inhibitors of microsomal triglyceride transfer protein have shown significant TG lowering efficacy. The current approach to the management of hypertriglyceridemia is based on lifestyle changes and, usually, drug combinations (statin and fibrate and/or omega-3 fatty acids or niacin).
Citace poskytuje Crossref.org
